Trials / Completed
CompletedNCT06295796
A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MK-8527 in Participants With Moderate and Severe Renal Impairment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The goal of this study is to evaluate the effect of moderate and severe renal impairment (RI) on the pharmacokinetics (PK), safety, and tolerability of MK-8527. There will be no hypothesis testing in the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-8527 | Oral Capsule |
Timeline
- Start date
- 2024-06-20
- Primary completion
- 2025-01-31
- Completion
- 2025-01-31
- First posted
- 2024-03-06
- Last updated
- 2026-02-17
- Results posted
- 2026-02-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06295796. Inclusion in this directory is not an endorsement.